- Hustle Hub Stocks
- Posts
- Regeneron Pharmaceuticals, Inc DCF Stock Analysis. Buy or Sell?
Regeneron Pharmaceuticals, Inc DCF Stock Analysis. Buy or Sell?
Regeneron Pharmaceuticals, Inc DCF Stock Analysis.
Home insurance rates up by 76% in some states
Over the last 6 years, home insurance rates have increased by up to 76% in some states. Between inflation, costlier repairs, and extreme weather, premiums are climbing fast – but that doesn’t mean you have to overpay. Many homeowners are saving hundreds a year by switching providers. Check out Money’s home insurance tool to compare companies and see if you can save.
Regeneron Pharmaceuticals, Inc DCF Stock Analysis.
Here’s my assumptions:
Risk Free Rate (10 Years Interest Rate Swap): 3.391%
Risk Premium (Taken from the Aswath Damodaran equity premium spreadsheet): 4.33%
Interest Rate Spread on The Risk free rate ( For the cost of debt calculation): 3%
Historical Data
Revenue growth in the last 10 years (CAGR): 13.22%
Earnings growth in the last 10 years (CAGR): 21.37%
Unlevered Free Cash Flow growth in the last 10 years (CAGR): 39.34%
Future Assumptions
End of Year FCF growth: 10%
Growth until end of 2026: 20%
Growth until end of 2034: 10%
Perpetual growth: 3%
Net Debt: 16.024B
Outstanding Stock Options Present Value Assumption: $0.804B
Restricted Stock Units Present Value Assumption: $1.630B
Stock Valuation based on these assumptions: $1320
Last update 11/08/2025
All the content in this newsletter should be taken as informational content only. THIS IS NOT FINANCIAL ADVICE! Do your own Due Diligence before investing or contact a professional financial advisor.
I don’t have a position in Regeneron Pharmaceuticals, Inc (REGN) and I don’t plan to add a position in the coming days.

